**Supplemental Figure 1.** Study design for DOT-DBS and TAF-DBS Studies. DOT-DBS and TAF-DBS were separate randomized, crossover studies, where participants received two different 12-week dosing regimens of 33%, 67% or 100% daily dosing, separated by a 12-week washout period. Blood was collected at weekly in TAF-DBS and bi-weekly in DOT-DBS. Concentrations in PBMC were quantified to characterize the steady-state and washout kinetics, at weeks 2, 4, 10, 12, 15, 26, 28, 34, and 36 in DOT-DBS and the same plus 4 hours after the first dose, then weeks 1, 3, 13, 14, 16, 17, 25, and 27 in TAF-DBS.

